256 related articles for article (PubMed ID: 18216099)
1. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
[TBL] [Abstract][Full Text] [Related]
2. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
3. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
[TBL] [Abstract][Full Text] [Related]
4. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
5. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
[TBL] [Abstract][Full Text] [Related]
6. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
McCormick AL; Parry CM; Crombe A; Goodall RL; Gupta RK; Kaleebu P; Kityo C; Chirara M; Towers GJ; Pillay D
Antimicrob Agents Chemother; 2011 Apr; 55(4):1806-9. PubMed ID: 21282419
[TBL] [Abstract][Full Text] [Related]
7. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
Brehm JH; Koontz DL; Wallis CL; Shutt KA; Sanne I; Wood R; McIntyre JA; Stevens WS; Sluis-Cremer N; Mellors JW;
Clin Infect Dis; 2012 Sep; 55(5):737-45. PubMed ID: 22618567
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
[TBL] [Abstract][Full Text] [Related]
10. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
Radzio J; Yap SH; Tachedjian G; Sluis-Cremer N
AIDS; 2010 Mar; 24(5):659-67. PubMed ID: 20160634
[TBL] [Abstract][Full Text] [Related]
11. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors.
Tanuma J; Hachiya A; Ishigaki K; Gatanaga H; Lien TT; Hien ND; Kinh NV; Kaku M; Oka S
Microbes Infect; 2010 Dec; 12(14-15):1170-7. PubMed ID: 20713171
[TBL] [Abstract][Full Text] [Related]
12. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
13. Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase.
Radzio J; Sluis-Cremer N
Retrovirology; 2011 Aug; 8():69. PubMed ID: 21859446
[TBL] [Abstract][Full Text] [Related]
14. Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.
Karubiu W; Bhakat S; Soliman ME
Protein J; 2014 Oct; 33(5):432-46. PubMed ID: 25107349
[TBL] [Abstract][Full Text] [Related]
15. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
16. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
[TBL] [Abstract][Full Text] [Related]
17. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations.
Vijayan RS; Arnold E; Das K
Proteins; 2014 May; 82(5):815-29. PubMed ID: 24174331
[TBL] [Abstract][Full Text] [Related]
19. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
[TBL] [Abstract][Full Text] [Related]
20. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
